July 02, 2025 01:00 ET | Source: BioVersys Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02,…
OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN:…
June 19, 2025 01:00 ET | Source: Addex Therapeutics Strong cash position of CHF2.8 million at end of Q1 2025GABAB…
June 12, 2025 16:53 ET | Source: Fobi AI Inc. Vancouver, BC, June 12, 2025 (GLOBE NEWSWIRE) -- FOBI AI…
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first…